1917 related articles for article (PubMed ID: 25667295)
1. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
2. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
4. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Schadendorf D; Wolchok JD; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Chesney J; Robert C; Grossmann K; McDermott D; Walker D; Bhore R; Larkin J; Postow MA
J Clin Oncol; 2017 Dec; 35(34):3807-3814. PubMed ID: 28841387
[TBL] [Abstract][Full Text] [Related]
6. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Maio M; Grob JJ; Aamdal S; Bondarenko I; Robert C; Thomas L; Garbe C; Chiarion-Sileni V; Testori A; Chen TT; Tschaika M; Wolchok JD
J Clin Oncol; 2015 Apr; 33(10):1191-6. PubMed ID: 25713437
[TBL] [Abstract][Full Text] [Related]
7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
9. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M; Mellor JD; McArthur G; Kee D
Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
[TBL] [Abstract][Full Text] [Related]
13. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
14. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Lebbé C; Weber JS; Maio M; Neyns B; Harmankaya K; Hamid O; O'Day SJ; Konto C; Cykowski L; McHenry MB; Wolchok JD
Ann Oncol; 2014 Nov; 25(11):2277-2284. PubMed ID: 25210016
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
20. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Ascierto PA; Del Vecchio M; Mackiewicz A; Robert C; Chiarion-Sileni V; Arance A; Lebbé C; Svane IM; McNeil C; Rutkowski P; Loquai C; Mortier L; Hamid O; Bastholt L; Dreno B; Schadendorf D; Garbe C; Nyakas M; Grob JJ; Thomas L; Liszkay G; Smylie M; Hoeller C; Ferraresi V; Grange F; Gutzmer R; Pikiel J; Hosein F; Simsek B; Maio M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
